New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:44 EDTHEBHemispherx reports evidence based clinical potential of IFN-alpha
Hemispherx Biopharma announced publication of an article entitled "Emergence of a novel drug resistant H7N9 influenza virus: Evidence based clinical potential of a natural IFN-alpha for infection control and treatment". H7N9 is a recently identified virus associated with high mortality in humans with the potential to emerge as an agent for a global pandemic. New cases of H7N9 have been very recently reported in China, Hong Kong and Taiwan. In vitro tests reported in the new article demonstrated that both oseltamivir and Alferon N have significant inhibitory effect on a neuraminidase inhibitor sensitive H7N9 influenza virus. In contrast, Alferon N, but not Tamiflu, had an inhibitory effect on the neuraminidase resistant Shanghai/1/H7N9 virus. According to the peer-reviewed article, "The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths in China. Because of the lack of existing immunity against H7 subtype influenza viruses in the human population and the absence of a licensed commercial vaccine, antiviral drugs are critical tools for the treatment of infection with this novel H7N9. Both M2-ion channel blockers and neuraminidase inhibitors are used as antiviral drugs for influenza infections of humans. The emerging H7N9 viruses are resistant to the M2-ion channel blockers because of a S31N mutation in the M2 protein; additionally, some H7N9 isolates have gained neuraminidase R292K substitution resulting in broad resistance to neuraminidase inhibitors. In this study we report that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro. Since Alferon N is approved for clinical use, this would allow a rapid regulatory approval process for this drug under pandemic threat."
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
08:35 EDTHEBHemispherx receives positive opinion on application for Orphan designation
Hemispherx Biopharma announces that the European subsidiary, "Hemispherx Biopharma Europe N.V./S.A" gained a positive opinion from the COMP (Committee on Medical Products) regarding its Orphan Medicinal Product Application for Ampligen, an experimental therapeutic, to treat Ebola Virus Disease, or EVD. The dossier submitted to the EU contained an inventory of relevant pre-clinical research in EVD therapeutically-oriented models, as well as, clinical safety information derived from non-EVD clinical studies of Ampligen. Of potentially high relevance to the favorable COMP opinion were experiments, conducted in Italy, which showed that, in vitro, Ampligen successfully competed with Ebola viral dsRNA in a manner which may result in loss of virulence by EBOV.
March 19, 2015
07:14 EDTHEBWall Street Analyst Forum to hold a conference
25th Annual Investor Conference is being held in New York on March 19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use